Cameco Corporation (CCJ)

The shares sit below their 20-day, 50-day and 200-day averages, and the 50-day average is itself below the 200-day, a configuration that points to a sustained downtrend. The stock is down 37.68% over six months and 22.68% over the past year, even as the company's revenue grew in its most recent available quarter. Trading at $72.87, the stock is 10% of the way up its 52-week range from the $66.06 low, and it fell 3.32% in the latest session. Analysts remain strongly positive, with 18 of 20 rating it Buy or Strong Buy, while CleaRank's own rating is Sell.

The stock has fallen 17.25% over the past month and 26.19% over three months, and it trades 46.12% below its 52-week high of $135.24. The trend is clearly down: the price sits 15.50% below its 50-day SMA and 29.01% below its 200-day SMA, and the 50-day average is 15.98% below the 200-day average. The 14-day RSI of 38.6 sits in the bearish zone, and the MACD line is negative, so momentum has not yet turned.

Earnings have not kept pace. Two of the last five reports beat EPS estimates. Earlier, the November 5, 2025 report missed by 74.07% and the shares fell 5.25%. Trailing GAAP EPS is $0.69, which leaves the P/E at 105.61.

At 105.61 times trailing earnings, the stock trades at a premium to peers, against a sector median P/E of 18.4. The price-to-sales ratio of 13.33 compares with a sector median of 2.5. Revenue grew in the most recent available quarter but only 0.70% year on year, well behind the sector median growth of 32.8%. Return on equity of 5.68% is below the sector median of 14.2%, although the balance sheet is light with a debt-to-equity ratio of 0.14.

Eighteen of 20 analysts rate the stock Buy or Strong Buy, two rate it Hold, and none rate it Sell, giving a Strong Buy consensus. Three months ago 20 of 22 ratings were Buy. The median 12-month target is $124.54, 70.9% above the price. Recent actions have been mostly reiterations: Barclays kept its Equal-Weight rating on November 2, 2026, and Truist Securities kept its Buy rating on October 22, 2026. CleaRank's rating of Sell is more cautious than Wall Street's consensus.

Recovering those averages would require earnings to stop missing estimates; the July 31, 2026 report came in at $0.18 against an estimate that was 52.63% higher, and the trailing P/E of 105.61 leaves little room for further disappointment. Analyst targets run from $83.69 to $172.06, with a median of $124.54, which implies substantial upside if the business recovers, but the consensus has not been enough to lift the shares so far. A move back toward the 200-day SMA at $102.64 would need rising revenue growth, which at 0.70% year on year trails the sector median of 32.8%. A break below the 52-week low of $66.06 would signal that the downtrend has extended and that the stock is testing new lows.

Support: the 52-week low at $66.06 is the nearest floor below the price and the level a further fall would meet first. Resistance: the 20-day EMA at $77.69 is the nearest level above the price and the first test for any rebound. The 50-day SMA at $86.23 comes next and marks where the medium-term trend would start to turn. The 200-day SMA at $102.64 is the longer-term average the stock has been trading well below. The 52-week high at $135.24 is the furthest reference point and would require a sustained rally to reach.